CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.

about

Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.

P2860

Q45233800-844AEB76-4803-469C-A828-A390DBA09576

P2860

CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.

Item

http://www.wikidata.org/entity/Q38726062

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

CREBBP knockdown enhances RAS/ ...... ate chemotherapeutic response.

@en

type

Item

label

CREBBP knockdown enhances RAS/ ...... ate chemotherapeutic response.

@en

prefLabel

CREBBP knockdown enhances RAS/ ...... ate chemotherapeutic response.

@en

P1476

CREBBP knockdown enhances RAS/ ...... late chemotherapeutic response

@en

P2093

Elizabeth Matheson

http://www.w3.org/2001/XMLSchema#string

Julie A E Irving

http://www.w3.org/2001/XMLSchema#string

Lindsay Nicholson

http://www.w3.org/2001/XMLSchema#string

Martin Zeppetzauer

http://www.w3.org/2001/XMLSchema#string

Paul Sinclair

http://www.w3.org/2001/XMLSchema#string

Zach A Dixon

http://www.w3.org/2001/XMLSchema#string

P2860

Acetylation is indispensable for p53 activation

Acute lymphoblastic leukaemia

Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.

Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration

Inactivating mutations of acetyltransferase genes in B-cell lymphoma

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.

CBP and p300: HATs for different occasions.

Expression of p300 and CBP is associated with poor prognosis in small cell lung cancer.

CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia

P304

736-745

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2016.145177

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

Christine J Harrison

P577

2016-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27979926

http://www.w3.org/2001/XMLSchema#string

P921

chemotherapy

P932

5395114

http://www.w3.org/2001/XMLSchema#string

CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.

about

P2860

P2860

CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932